SLC5A2 and diabetes mellitus: Because it was recently reported that weight loss was associated with reduction of liver weight and the hepatic triglyceride content after SGLT2 therapy in rodent diabetes models [23], the weight loss seen in this study could be associated with a mechanism other than improvement of visceral fat by calorie loss.